BERLIN (Reuters) -CureVac will withdraw its first-generation COVID-19 vaccine candidate and focus on collaborating with GSK to develop second-generation mRNA […]
BEIJING (Reuters) -A potential COVID-19 vaccine from China’s Clover Biopharmaceuticals was 67% effective against COVID-19 of any degree of severity […]